biosimilars Asia
Biosimilar Capabilities and Market Potential in Asia
June 29 by Pharma IQEpogen, Neupogen and Enbrel are three biologics which have already seen their patents expire, and Herceptin and Avastin are to be added to this list in the not too distant future. By 2015 the global...
Realising the Demand for Affordable Healthcare: Opportunities and Challenges
May 11 by Pharma IQAsia looks to be at the forefront of growth within the pharmaceutical industry in the next few years, particularly the emerging markets of India and China. Costs of drug development in the region...
